VolitionRX Showcases Innovative Lung Cancer Detection Findings at European Conference

VolitionRX Unveils Promising Findings for Lung Cancer Management at ELCC

VolitionRX Limited, an epigenetics company specializing in innovative cancer detection techniques, showcases groundbreaking research at the European Lung Cancer Conference (ELCC) in Copenhagen. The focus of this presentation revolves around the company's Nu.Q® Cancer assays, which hold the potential to transform management strategies for Non Small Cell Lung Cancer (NSCLC). Dr. Pei-Hsing Chen from National Taiwan University Hospital leads an insightful study that highlights how measuring preoperative H3K27Me3-nucleosomes using Volition's blood test can identify NSCLC patients in need of enhanced follow-up or secondary treatments. This approach represents a significant evolution in cancer diagnostics, allowing for more personalized and precision-based healthcare interventions.

The study reveals a compelling correlation between elevated levels of H3K27Me3-nucleosomes and poorer recurrence-free and overall survival rates in patients. Conversely, lower levels of these nucleosomes indicate a notably better prognosis. This innovative assay also presents the ability to detect micro-metastatic disease, further informing treatment strategies for patients categorized as high-risk. With the medical community's increasing emphasis on individualized treatment paradigms, this development underscores the essential role of precision medicine in improving patient outcomes.

Dr. Andrew Retter, a medical consultant at Volition, emphasizes the broader implications of the Nu.Q® Cancer technology for clinical practice. He asserts that this approach not only enhances treatment selection precision but also substantially improves prognostication for patients facing lung cancer. The research—in collaboration with long-standing partners from Taiwan and Lyon—reinforces Volition's mission of leveraging epigenetic advancements to save lives. The findings articulated during the conference, specifically poster 244P, affirm the company’s ongoing commitment to advancing lung cancer management through pioneering scientific approaches.

In addition to the main presentation, VolitionRX's abstract references past studies highlighting the strong prognostic capabilities of circulating nucleosomes in lung cancer contexts. These insights are pivotal for fostering deeper understanding and clinical implementation of the Nu.Q® Cancer assays in routine practice, ultimately steering patient care towards more informed and effective pathways.

VolitionRX’s participation in the ELCC not only showcases its cutting-edge research but also reflects a steadfast dedication to revolutionizing the standards of lung cancer diagnostics. The promising results of the H3K27Me3-nucleosome assay are poised to empower healthcare providers while aligning with the company’s overarching goal of improving patient outcomes and enhancing the quality of life for those battling lung cancer.